IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dario CARRARA et al. Confirmation No.: 5916

Application No.: 10/798,111 Group Art Unit: 1616

Filing Date: March 10, 2004 Examiner: Konata M. George

For: METHODS AND FORMULATIONS Atty. Docket No.: 88066-7900

FOR TRANSDERMAL OR

TRANSMUCOSAL APPLICATION OF

ACTIVE AGENTS

TERMINAL DISCLAIMER

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Petitioner, Allan A. Fanucci, represents that he is the attorney of record for the present application.

Petitioner states that he has reviewed the assignment document that was recorded for the present application on June 4, 2004 at Reel 015436 Frame 0299, and the assignment document that was recorded for US patent 7,198,801 on June 24, 2004 at Reel 015510 Frame 0045 and confirms that Antares Pharma IPL is the owner of both the above-identified application and US patent 7,198,801.

Petitioner hereby disclaims the terminal part of any patent granted on the above-identified application that would extend beyond the term of US patent 7,198,801, and hereby agrees that any patent so granted on the above-identified application shall be enforceable only for and during such period that any patent granted on the present application and US patent 7,198,801 are commonly owned.

Petitioner further agrees that this agreement is to run with any patent granted on the above-identified application and is to be binding upon the grantees, their successors, and their assigns. Petitioner does not disclaim any terminal part of any patent that issues on the above-identified application prior to the expiration date of US patent 7,198,801 in the event that that any such patent is held unenforceable, is found invalid, is statutorily disclaimed in whole or in part or is terminally disclaimed under 37 C.F.R. § 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to the expiration of its full 20 year statutory term, except for lack of common ownership as stated above.

Petitioner hereby declares that all statements made herein of his own knowledge and belief are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application and any patent issuing thereon.

Signed this first day of October, 2007.

Allan A. Fanucci

Reg. No. 30.256

WINSTON & STRAWN LLP CUSTOMER NO. 28765 (212) 294-3311

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Dario CARRARA et al.

Confirmation No.: 5916

Application No.: 10/798,111

Group Art Unit: 1616

Filing Date: March 10, 2004

Examiner: Konata M. George

Atty. Docket No.: 88066-7900

For:

METHODS AND FORMULATIONS

FOR TRANSDERMAL OR

TRANSMUCOSAL APPLICATION OF

ACTIVE AGENTS

FEE AUTHORIZATION TRANSMITTAL

Commissioner For Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

The fees which are believed to be due for the submission of the concurrently filed terminal disclaimer is \$110. No other fees are believed to be due for this submission. Please charge any and all required fees for processing these documents, including any fees for requesting an extension of time for responding if applicable, to WINSTON & STRAWN LLP Deposit Account No. 50-1814.

Respectfully submitted,

Allan A. Fanucci

WINSTON & STRAWN LLP

Customer No. 28765

(212) 294-3311